First use of Creatine Hydrochloride in Premanifest Huntington Disease


Huntington disease is a devastating autosomal dominant neurodegenerative disorder that typically manifests between ages 30 and 50 years. Promising high-dose creatine monophosphate trials have been limited by patient tolerance.

This is the first report of use of creatine hydrochloride in two premanifest Huntington disease patients, with excellent tolerability over more than 2 years of use.


Learning Outcomes

  1. Understand of treatment outcomes with creatine hydrochloride in two premanifest Huntington disease patients


Medical Audience
GP, GP Registrar, Specialist, Doctors in Training (DIT), Medical Student, International Medical Graduate, Overseas Trained Doctor


Medical Journal of Australia
Reading: journal; textbook; book; literature review
0h : 30m
MBA: 0h : 30m
ACRRM - Fellow: 0.5 pts
ACRRM - Non Fellow: 0.5 pts
RACGP: 1 pt
Medical Genetics

You have to be logged in to see the content of this module.

Provided by